Investigational Drug Information for Barusiban
✉ Email this page to a colleague
What is the drug development status for Barusiban?
Barusiban is an investigational drug.
There have been 4 clinical trials for Barusiban.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2016.
The most common disease conditions in clinical trials are Obstetric Labor, Premature, Infertility, and Premature Birth. The leading clinical trial sponsors are Ferring Pharmaceuticals, Tel-Aviv Sourasky Medical Center, and [disabled in preview].
There are ten US patents protecting this investigational drug and one hundred and sixty-three international patents.
Summary for Barusiban
| US Patents | 10 |
| International Patents | 163 |
| US Patent Applications | 36 |
| WIPO Patent Applications | 35 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 2 (2016-03-01) |
| Vendors | 10 |
Recent Clinical Trials for Barusiban
| Title | Sponsor | Phase |
|---|---|---|
| Tocolytic Therapy for Preterm Labor in Multiple Gestation | Tel-Aviv Sourasky Medical Center | Phase 3 |
| Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions | Ferring Pharmaceuticals | Phase 2 |
| Effect of Oxytocin Antagonist on Reduction of Uterine Contractions | Ferring Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Barusiban
Top disease conditions for Barusiban
Top clinical trial sponsors for Barusiban
US Patents for Barusiban
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Barusiban | ⤷ Try a Trial | Permeant delivery system and methods for use thereof | NITTO DENKO CORPORATION (Tokyo, JP) | ⤷ Try a Trial |
| Barusiban | ⤷ Try a Trial | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof | Merck Serono S.A. (Coinsins, CH) | ⤷ Try a Trial |
| Barusiban | ⤷ Try a Trial | 1H-pyrazoles useful in therapy | Pfizer Inc (New York, NY) | ⤷ Try a Trial |
| Barusiban | ⤷ Try a Trial | Pyrrolidines | Pfizer Inc. (New York, NY) | ⤷ Try a Trial |
| Barusiban | ⤷ Try a Trial | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | Ascendis Pharma AS (Hellerup, DK) | ⤷ Try a Trial |
| Barusiban | ⤷ Try a Trial | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | ProLynx LLC (San Francisco, CA) | ⤷ Try a Trial |
| Barusiban | ⤷ Try a Trial | .alpha.-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof | Merck Serono S.A. (Coinsins, CH) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Barusiban
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Barusiban | Australia | AU2009231739 | 2028-03-31 | ⤷ Try a Trial |
| Barusiban | Canada | CA2720067 | 2028-03-31 | ⤷ Try a Trial |
| Barusiban | Canada | CA3084317 | 2028-03-31 | ⤷ Try a Trial |
| Barusiban | Canada | CA3138128 | 2028-03-31 | ⤷ Try a Trial |
| Barusiban | China | CN102088935 | 2028-03-31 | ⤷ Try a Trial |
| Barusiban | China | CN105126241 | 2028-03-31 | ⤷ Try a Trial |
| Barusiban | European Patent Office | EP2268244 | 2028-03-31 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
